Compounds of formula (I): ##STR00001## wherein R.sup.1 represents
optionally substituted C.sub.4-12 alkyl, optionally substituted
C.sub.2-6alkylaryl, or optionally substituted 5- or 6-membered aryl or
heteroaryl; Z represents a bond, CH.sub.2, O, S, SO, SO.sub.2, NR.sup.4,
OCR.sup.4R.sup.5, CR.sup.4R.sup.5O, or Z, R.sup.1 and Q together form an
optionally substituted fused tricyclic group; Q represents an optionally
substituted 5- or 6-membered aryl or heteroaryl ring; X represents
COR.sup.3 or N(OR.sup.8)COR.sup.9; R.sup.2 represents SO.sub.2R.sup.10 or
SO.sub.2NR.sup.10R.sup.11; R.sup.3 represents OR.sup.6, NR.sup.6R.sup.7
or NR.sup.6OH; R.sup.4 and R.sup.5 each independently represents H,
C.sub.1-6 alkyl or C.sub.1-4 alkylaryl; R.sup.6 and R.sup.7 each
independently represents H, C.sub.1-6 alkyl, or C.sub.1-6 alkyl
substituted with one or more heteroaryl groups, or R.sup.6 and R.sup.7
together with the nitrogen atom to which they are attached form a 5- or
6-membered ring which may optionally include 1 or more further
heteroatoms selected from O, S and N; R.sup.8 and R.sup.9 each
independently represents H or C.sub.1-6 alkyl; R.sup.10 and R.sup.11 each
independently represents H or C.sub.1-6 alkyl; and and physiologically
functional derivatives thereof, with the exception of
N-(ethoxycarbonyl)-N-[4-(1H-tetrazol-1-yl)phenyl]glycine, processes for
their preparation, pharmaceutical formulations containing them and their
use as inhibitors of matrix metalloproteinase enzymes (MMPs) are
described.